NCT00912015已完成3 期
A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 238
- 主要终点
- Adverse Events: 12-months Safety Population
研究概览
简要总结
The purpose of this study is to evaluate the long-term safety (up to one year) of Tramadol Once-A-Day (OAD) tablets at the highest doses: 200-400 mg
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis of the knee consistent with the ACR Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):
- •Current knee pain,
- •Less than 30 minutes of morning stiffness with or without crepitus on active motion.
- •Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within one year prior to entry into the study.
- •ESR < 40 mm/hour
- •WOMAC Pain Subscales total score of more than or equal to 150 mm at baseline.
- •Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.
- •The Patient has signed and dated the REB approved, written, informed consent prior to study participation.
排除标准
- •Known rheumatoid arthritis or any other rheumatoid disease.
- •Secondary arthritis, i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.
- •Obesity Class II (BMI more than or equal to 35) (NIH, 2000)
- •Major illness requiring hospitalization during the 3 months before commencement of the screening period.
- •Unwillingness to cease taking medication other than the study medication for arthritic pain, any other concomitant pain, or OA medications.
- •Patients who have previously failed tramadol HCl therapy or those who discontinued tramadol HCl due to adverse events.
- •Patients who are taking or within the last 3 weeks have taken the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.
- •Patients who are taking or have taken another investigational agent within the last 30 days.
- •Patients with a history of seizure disorder other than Infantile Febrile Seizures.
- •Patients who are opioid dependent.
- •Patients with bowel disease causing malabsorption.
- •Patients who are pregnant or lactating or patients of child-bearing potential who are unwilling to utilize a medically approved method of contraception during participation in this clinical trial.
- •Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
- •Patients with significant renal disease, defined as creatinine clearance <30 mL/min as estimated by the method of Levey et al.,
- •Current substance abuse or dependence, other than nicotine.
- •Allergy or adverse reaction to tramadol or any structurally similar drugs e.g. opiates.
- •Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.
研究组 & 干预措施
Tramadol OAD 200mg
Experimental
干预措施: Tramadol OAD (Drug)
Tramadol OAD 300mg
Experimental
干预措施: Tramadol OAD (Drug)
Tramadol OAD 400mg
Experimental
干预措施: Tramadol OAD (Drug)
Tramadol OAD 100mg
Other
Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
干预措施: Tramadol OAD 100mg (Drug)
结局指标
主要结局
Adverse Events: 12-months Safety Population
时间窗: 12 months
Spontaneous adverse events were recorded for patients who received the same dose for at least 350 days. A treatment emergent adverse event (TEAE) was associated to the dose level on which a patient was 2 days prior to the TEAE. Only TEAEs which could be associated with the dose level on which the patient was for the longest time were considered.
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)PainNCT00852917Labopharm Inc.552
已完成
3 期
A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the KneePainOsteoarthritis, KneeNCT00832416Labopharm Inc.565
已完成
4 期
An Efficacy and Safety Study of Tramadol Hydrochloride-Paracetamol in Treatment of Moderate to Severe Acute Neck-Shoulder Pain and Low Back PainLow Back PainShoulder PainNeck PainNCT01843660Xian-Janssen Pharmaceutical Ltd.1,059
已完成
4 期
A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic NeuropathyDiabetic NeuropathyNCT00634543Janssen Korea, Ltd., Korea162
已完成
3 期
A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.Chronic PainNCT00347685Bausch Health Americas, Inc.650